Speaker Profile

Co-founder & CEO, Microbiome Insights

Biography
Malcolm Kendall has over 28 years of operational management, entrepreneurial, venture capital investment and leadership experience, the majority of which has been focused on company creation and building value in technology and biotechnology companies. Before founding Microbiome Insights, he was the co-founder and CEO of Indel Therapeutics Inc., a Vancouver-based biopharmaceutical company dedicated to developing new drugs to address the global health crisis caused by antibiotic resistance. Prior to this, Malcolm was an investment professional with life science focused venture capital firms MDS Capital (now Lumira Capital), BioVista Capital (now Hatteras Venture Partners) and Intersouth Partners. Before entering business, he served in the U.S. Army where he honed his leadership skills as an Infantry and Special Forces officer. Malcolm has been an advisor and board member to numerous companies and organizations and is currently a member of the board of directors of Semios BIO Technologies, a mentor for the [email protected] program and an adjunct professor at the MBA MOT program at Simon Fraser University. He received his undergraduate degree from Washington and Lee University and an M.B.A. from the Kenan-Flagler Business School at the University of North Carolina.

Talk
A Microbiome-Based Test For Inflammatory Bowel Disease
The microbiome plays a role in the pathogenesis of Inflammatory Bowel Disease (IBD). Clinical utility of a microbiome-based test for IBD will be determined by its correlation to clinical endpoints and its effectiveness for monitoring disease. Microbiome Insights is developing a novel microbiome-based test to monitor disease activity in IBD.


 Session Abstract – PMWC 2020 Silicon Valley


The PMWC 2020 Microbial Profiling Showcase will provide a 15-minute time slot for selected companies in the Microbiome and Pathogen ID fields. The human microbiome is composed of a wide variety of microorganisms that are essential for maintaining human health and preventing disease. Research in this area is accelerating due to the rapid development in genome sequencing technologies. This showcase will present some of the leading companies in microbial profiling and pathogen identification.